JP2018139586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018139586A5 JP2018139586A5 JP2018041788A JP2018041788A JP2018139586A5 JP 2018139586 A5 JP2018139586 A5 JP 2018139586A5 JP 2018041788 A JP2018041788 A JP 2018041788A JP 2018041788 A JP2018041788 A JP 2018041788A JP 2018139586 A5 JP2018139586 A5 JP 2018139586A5
- Authority
- JP
- Japan
- Prior art keywords
- replicable
- virus
- protein
- cancer
- virus according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1507419.8 | 2015-04-30 | ||
| GBGB1507419.8A GB201507419D0 (en) | 2015-04-30 | 2015-04-30 | Virus |
| GBGB1516936.0A GB201516936D0 (en) | 2015-09-24 | 2015-09-24 | Virus |
| GB1516936.0 | 2015-09-24 | ||
| GB1522013.0 | 2015-12-14 | ||
| GBGB1522013.0A GB201522013D0 (en) | 2015-12-14 | 2015-12-14 | Virus |
| JP2017552966A JP6931229B2 (ja) | 2015-04-30 | 2016-04-29 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552966A Division JP6931229B2 (ja) | 2015-04-30 | 2016-04-29 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018139586A JP2018139586A (ja) | 2018-09-13 |
| JP2018139586A5 true JP2018139586A5 (https=) | 2019-05-30 |
| JP6928380B2 JP6928380B2 (ja) | 2021-09-01 |
Family
ID=56008588
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552966A Active JP6931229B2 (ja) | 2015-04-30 | 2016-04-29 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
| JP2018041788A Active JP6928380B2 (ja) | 2015-04-30 | 2018-03-08 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
| JP2021129196A Active JP7162929B2 (ja) | 2015-04-30 | 2021-08-05 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552966A Active JP6931229B2 (ja) | 2015-04-30 | 2016-04-29 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021129196A Active JP7162929B2 (ja) | 2015-04-30 | 2021-08-05 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US11000559B2 (https=) |
| EP (2) | EP3391892A1 (https=) |
| JP (3) | JP6931229B2 (https=) |
| KR (4) | KR102854512B1 (https=) |
| CN (2) | CN107690479B (https=) |
| AU (3) | AU2016256582B2 (https=) |
| BR (2) | BR112017023171A2 (https=) |
| CA (1) | CA2984038C (https=) |
| CL (2) | CL2017002731A1 (https=) |
| CO (1) | CO2017010831A2 (https=) |
| CY (1) | CY1122833T1 (https=) |
| DK (1) | DK3288573T3 (https=) |
| EA (1) | EA037611B1 (https=) |
| ES (1) | ES2780366T3 (https=) |
| HR (1) | HRP20200439T1 (https=) |
| HU (1) | HUE048320T2 (https=) |
| IL (3) | IL284375B (https=) |
| LT (1) | LT3288573T (https=) |
| MX (1) | MX2017013684A (https=) |
| MY (1) | MY183703A (https=) |
| PE (2) | PE20181140A1 (https=) |
| PH (1) | PH12017501942A1 (https=) |
| PL (1) | PL3288573T3 (https=) |
| PT (1) | PT3288573T (https=) |
| RS (1) | RS60105B1 (https=) |
| SA (2) | SA520412637B1 (https=) |
| SG (3) | SG10201803081TA (https=) |
| SI (1) | SI3288573T1 (https=) |
| SM (1) | SMT202000222T1 (https=) |
| WO (1) | WO2016174200A1 (https=) |
| ZA (1) | ZA201801589B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2914790C (en) | 2013-06-14 | 2024-02-27 | Psioxus Therapeutics Limited | A dosing regime and formulations for type b adenoviruses |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| HUE035875T2 (hu) | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| BR112018012180A2 (pt) * | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| JP7466271B2 (ja) * | 2016-03-31 | 2024-04-12 | ザ ヨーロピアン モレキュラー バイオロジー ラボラトリー | アデノウイルスコートタンパク質由来送達賦形剤 |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| IL303187A (en) | 2016-08-29 | 2023-07-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| ES2981703T3 (es) | 2016-09-02 | 2024-10-10 | Lentigen Tech Inc | Composiciones y métodos para tratar cáncer con DuoCars |
| JP7138946B2 (ja) * | 2016-09-27 | 2022-09-20 | セイター セラピューティクス エルエルシー | 最適化された腫瘍溶解性ウイルスおよびその使用 |
| WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| JP7724601B2 (ja) * | 2017-02-03 | 2025-08-18 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| KR20190139216A (ko) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
| EP3630144A4 (en) * | 2017-05-25 | 2021-03-31 | University of Central Florida Research Foundation, Inc. | NEW ONCOLYTIC VIRUSES TO SENSITIZE TUMOR CELLS TO DESTRUCTION BY NATURAL KILLER CELLS |
| JP7216668B2 (ja) | 2017-05-26 | 2023-02-01 | エピセントアールエックス，インコーポレイテッド | 導入遺伝子を保持する組換えアデノウイルス |
| DK3630143T5 (da) | 2017-06-01 | 2024-09-02 | Akamis Bio Ltd | Onkolytisk virus og fremgangsmåde |
| WO2019147921A1 (en) * | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
| GB201801614D0 (en) * | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| WO2019173334A1 (en) * | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
| KR20200136972A (ko) * | 2018-03-30 | 2020-12-08 | 도모키 도도 | 종창 발생 억제형 종양 용해성 바이러스 |
| WO2020052551A1 (en) * | 2018-09-10 | 2020-03-19 | Genesail Biotech (Shanghai) Co. Ltd. | A modified oncolytic virus, composition and use thereof |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
| EA202192420A1 (ru) * | 2019-03-05 | 2021-12-13 | Эмджен Инк. | Применение онколитических вирусов для лечения рака |
| EP3725323A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
| US20220249127A1 (en) * | 2019-05-14 | 2022-08-11 | Oncolys Biopharma Inc. | Method for administering oncolytic virus to tumor tissue, and device for administration |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| WO2022252185A1 (zh) * | 2021-06-03 | 2022-12-08 | 上海允英生物医药科技有限公司 | 溶瘤病毒载体及其应用 |
| CA3233100A1 (en) | 2021-09-23 | 2023-03-30 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
| EP4499846A1 (en) * | 2022-03-25 | 2025-02-05 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| AU2024277678A1 (en) | 2023-05-25 | 2025-11-27 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| SK282843B6 (sk) | 1993-07-13 | 2002-12-03 | Rhone-Poulenc Rorer S. A. | Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
| EP1036183B1 (en) | 1997-02-20 | 2007-10-03 | The Johns Hopkins University School Of Medicine | Mutations in atp-dependent transposition proteins that reduce target-site specificity |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| US6455314B1 (en) | 1998-09-11 | 2002-09-24 | Genvec, Inc. | Alternatively targeted adenovirus |
| DK1137792T3 (da) | 1998-12-09 | 2007-09-10 | Us Gov Health & Human Serv | En rekombinant vektor, der udtrykker adskillige costimulatoriske molekyler, og anvendelser deraf |
| ES2372823T3 (es) | 1999-05-17 | 2012-01-26 | Crucell Holland B.V. | Adenovirus recombinante del serotipo ad11. |
| EP1181382B1 (en) | 1999-06-01 | 2005-03-23 | The University of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| GB2375113B (en) | 2000-01-21 | 2004-10-20 | Biovex Ltd | A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| WO2001092549A2 (en) | 2000-05-31 | 2001-12-06 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| ATE449859T1 (de) | 2001-01-04 | 2009-12-15 | Goeran Wadell | Virusvektor zur gentherapie |
| US20050175589A1 (en) | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| CA2474777A1 (en) | 2002-02-01 | 2003-08-07 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
| CN1705740B (zh) * | 2002-10-15 | 2013-07-24 | 佩尔·松内·霍尔姆 | 具有反向基因表达的腺病毒及其应用 |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| WO2004087930A1 (en) | 2003-03-28 | 2004-10-14 | Saint Louis University | Adenovirus replication-competent vectors expressing trail |
| US20050136035A1 (en) | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US20050036989A1 (en) | 2003-07-18 | 2005-02-17 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
| US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| US20080292592A1 (en) | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
| BRPI0510475B8 (pt) * | 2004-05-26 | 2021-05-25 | Bayer Pharma AG | adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| US20060292682A1 (en) * | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| CN101068933A (zh) * | 2004-08-25 | 2007-11-07 | 细胞基因系统有限公司 | 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体 |
| EP1784493A2 (en) * | 2004-09-01 | 2007-05-16 | The Government of the United States of America as Represented by The Department of Health and Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| US20090208924A1 (en) | 2004-12-01 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Generation of Replication Competent Viruses for Therapeutic Use |
| BRPI0615400A2 (pt) | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| WO2008080003A2 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
| EP2296678A4 (en) | 2008-05-27 | 2012-03-21 | Oncolytics Biotech Inc | MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION |
| CN101381742A (zh) * | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| WO2011043719A1 (en) * | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
| CN103237889B (zh) | 2010-08-16 | 2017-04-05 | 萨克生物研究学院 | 腺病毒组装方法 |
| US20130323205A1 (en) * | 2010-09-24 | 2013-12-05 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| US20130243731A1 (en) | 2010-09-24 | 2013-09-19 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| JP2015507604A (ja) | 2011-11-14 | 2015-03-12 | リジェネレイティブ サイエンシーズ， エルエルシー | 懸濁粒子送達システムおよび方法 |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
| WO2014138314A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| HUE035875T2 (hu) * | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| CN106029889A (zh) | 2013-11-22 | 2016-10-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| GB201510197D0 (en) * | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| AU2016232009B2 (en) | 2015-03-17 | 2021-07-15 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| CN109312364A (zh) | 2016-03-18 | 2019-02-05 | 河谷细胞有限公司 | 用于感染树突状细胞的多模式载体 |
| IL303187A (en) | 2016-08-29 | 2023-07-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| WO2018075978A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| DK3630143T5 (da) * | 2017-06-01 | 2024-09-02 | Akamis Bio Ltd | Onkolytisk virus og fremgangsmåde |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2016
- 2016-04-29 HR HRP20200439TT patent/HRP20200439T1/hr unknown
- 2016-04-29 EP EP18159326.0A patent/EP3391892A1/en active Pending
- 2016-04-29 MX MX2017013684A patent/MX2017013684A/es unknown
- 2016-04-29 SG SG10201803081TA patent/SG10201803081TA/en unknown
- 2016-04-29 CN CN201680024692.0A patent/CN107690479B/zh active Active
- 2016-04-29 PL PL16723043T patent/PL3288573T3/pl unknown
- 2016-04-29 PE PE2018000519A patent/PE20181140A1/es unknown
- 2016-04-29 US US15/570,100 patent/US11000559B2/en active Active
- 2016-04-29 KR KR1020247006825A patent/KR102854512B1/ko active Active
- 2016-04-29 RS RS20200325A patent/RS60105B1/sr unknown
- 2016-04-29 BR BR112017023171-9A patent/BR112017023171A2/pt active Search and Examination
- 2016-04-29 KR KR1020177032425A patent/KR102643574B1/ko active Active
- 2016-04-29 PE PE2017002327A patent/PE20180241A1/es unknown
- 2016-04-29 LT LTEP16723043.2T patent/LT3288573T/lt unknown
- 2016-04-29 CN CN201810213204.1A patent/CN108396015B/zh active Active
- 2016-04-29 EP EP16723043.2A patent/EP3288573B1/en active Active
- 2016-04-29 DK DK16723043.2T patent/DK3288573T3/da active
- 2016-04-29 EA EA201791971A patent/EA037611B1/ru unknown
- 2016-04-29 JP JP2017552966A patent/JP6931229B2/ja active Active
- 2016-04-29 PT PT167230432T patent/PT3288573T/pt unknown
- 2016-04-29 ES ES16723043T patent/ES2780366T3/es active Active
- 2016-04-29 IL IL284375A patent/IL284375B/en unknown
- 2016-04-29 BR BR122018004815A patent/BR122018004815A2/pt not_active Application Discontinuation
- 2016-04-29 SI SI201630679T patent/SI3288573T1/sl unknown
- 2016-04-29 CA CA2984038A patent/CA2984038C/en active Active
- 2016-04-29 SG SG11201708604TA patent/SG11201708604TA/en unknown
- 2016-04-29 SG SG10201901482XA patent/SG10201901482XA/en unknown
- 2016-04-29 HU HUE16723043A patent/HUE048320T2/hu unknown
- 2016-04-29 MY MYPI2017703967A patent/MY183703A/en unknown
- 2016-04-29 WO PCT/EP2016/059609 patent/WO2016174200A1/en not_active Ceased
- 2016-04-29 KR KR1020187030538A patent/KR20180118249A/ko not_active Withdrawn
- 2016-04-29 AU AU2016256582A patent/AU2016256582B2/en active Active
- 2016-04-29 KR KR1020257028976A patent/KR20250134212A/ko active Pending
- 2016-04-29 SM SM20200222T patent/SMT202000222T1/it unknown
- 2016-08-08 US US15/231,422 patent/US10124028B2/en active Active
-
2017
- 2017-05-03 US US15/586,091 patent/US10548929B2/en active Active
- 2017-10-25 PH PH12017501942A patent/PH12017501942A1/en unknown
- 2017-10-25 CO CONC2017/0010831A patent/CO2017010831A2/es unknown
- 2017-10-26 CL CL2017002731A patent/CL2017002731A1/es unknown
- 2017-10-26 IL IL255286A patent/IL255286B/en active IP Right Grant
- 2017-10-30 SA SA520412637A patent/SA520412637B1/ar unknown
- 2017-10-30 SA SA517390260A patent/SA517390260B1/ar unknown
- 2017-10-31 US US15/799,644 patent/US10322152B2/en active Active
-
2018
- 2018-02-28 AU AU2018201446A patent/AU2018201446B2/en active Active
- 2018-03-05 CL CL2018000587A patent/CL2018000587A1/es unknown
- 2018-03-07 ZA ZA201801589A patent/ZA201801589B/en unknown
- 2018-03-08 JP JP2018041788A patent/JP6928380B2/ja active Active
- 2018-03-12 IL IL258044A patent/IL258044B/en unknown
- 2018-09-18 US US16/134,704 patent/US10849945B2/en active Active
-
2020
- 2020-03-18 CY CY20201100253T patent/CY1122833T1/el unknown
- 2020-08-25 AU AU2020223665A patent/AU2020223665A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/301,502 patent/US20210338753A1/en not_active Abandoned
- 2021-08-05 JP JP2021129196A patent/JP7162929B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018139586A5 (https=) | ||
| Zhao et al. | Oncolytic adenovirus: prospects for cancer immunotherapy | |
| Li et al. | CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy | |
| JP2020531032A5 (https=) | ||
| Yamamoto et al. | Recent advances in genetic modification of adenovirus vectors for cancer treatment | |
| JP2018514199A5 (https=) | ||
| JP2020517635A5 (https=) | ||
| JP2021533789A5 (https=) | ||
| JP2017514483A5 (https=) | ||
| Hernandez-Alcoceba et al. | Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12 | |
| WO2020037206A4 (en) | Recombinant myxoma viruses and uses thereof | |
| JP2018505893A5 (https=) | ||
| WO2015182574A1 (ja) | Ｒｅｉｃ遺伝子を発現する制限増殖型アデノウイルス | |
| CN103614416A (zh) | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 | |
| EP3720882A1 (en) | T-cells comprising two different chimeric antigen receptors and uses thereof | |
| WO2011081294A2 (ko) | 항혈관신생 활성을 가지는 재조합 아데노바이러스 | |
| JP2024510712A (ja) | Ｉｌ－１５をコードするアデノウイルス | |
| JP7381604B2 (ja) | 癌を治療するための多価ｐｄ－ｌ１結合化合物 | |
| Nistal-Villan et al. | Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model | |
| JP2021528367A5 (https=) | ||
| JP2021522190A5 (https=) | ||
| Han et al. | Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell | |
| RU2016142370A (ru) | Новые медицинские агенты и их применение | |
| WO2023196550A2 (en) | Adenovirus constructs and methods of use | |
| Akbulut et al. | Antitumor immune response induced by it injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer |